Book contents
- High-Risk Pregnancy: Management Options
- High-Risk Pregnancy: Management Options
- Copyright page
- Contents
- Contributors
- Section 1 Prepregnancy Problems
- Section 2 Early Prenatal Problems
- Section 3 Late Prenatal – Fetal Problems
- Chapter 9 Prenatal Fetal Surveillance (Content last reviewed: 15th December 2018)
- Chapter 10 Fetal Growth Disorders (Content last reviewed: 15th March 2020)
- Chapter 11 Disorders of Amniotic Fluid (Content last reviewed: 15th March 2020)
- Chapter 12 Fetal Hemolytic Disease (Content last reviewed: 15th February 2018)
- Chapter 13 Fetal Thrombocytopenia (Content last reviewed: 15th March 2020)
- Chapter 14 Fetal Cardiac Arrhythmias (Content last reviewed: 15th March 2020)
- Chapter 15 Fetal Cardiac Abnormalities (Content last reviewed: 15th March 2020)
- Chapter 16 Fetal Craniospinal and Facial Abnormalities
- Chapter 17 Fetal Genitourinary Abnormalities (Content last reviewed: 15th March 2020)
- Chapter 18 Fetal Gastrointestinal and Abdominal Abnormalities (Content last reviewed: 15th February 2018)
- Chapter 19 Fetal Skeletal Abnormalities
- Chapter 20 Fetal Tumors (Content last reviewed: 15th February 2018)
- Chapter 21 Fetal Hydrops (Content last reviewed: 15th March 2020)
- Chapter 22 Fetal Death
- Section 4 Problems Associated with Infection
- Chapter 24 Hepatitis Virus Infections in Pregnancy (Content last reviewed: 23rd July 2019)
- Chapter 25 Human Immunodeficiency Virus in Pregnancy (Content last reviewed: 23rd July 2019)
- Chapter 26 Rubella, Measles, Mumps, Varicella, and Parvovirus in Pregnancy (Content last reviewed: 11th November 2020)
- Chapter 27 Cytomegalovirus, Herpes Simplex Virus, Adenovirus, Coxsackievirus, and Human Papillomavirus in Pregnancy (Content last reviewed: 11th November 2020)
- Chapter 28 Parasitic Infections in Pregnancy (Content last reviewed: 15th June 2018)
- Chapter 29 Other Infectious Conditions in Pregnancy (Content last reviewed: 11th November 2020)
- Section 5 Late Pregnancy – Maternal Problems
- Section 6 Late Prenatal – Obstetric Problems
- Section 7 Postnatal Problems
- Section 8 Normal Values
- Index
- References
Chapter 13 - Fetal Thrombocytopenia (Content last reviewed: 15th March 2020)
from Section 3 - Late Prenatal – Fetal Problems
Published online by Cambridge University Press: 15 November 2017
Book contents
- High-Risk Pregnancy: Management Options
- High-Risk Pregnancy: Management Options
- Copyright page
- Contents
- Contributors
- Section 1 Prepregnancy Problems
- Section 2 Early Prenatal Problems
- Section 3 Late Prenatal – Fetal Problems
- Chapter 9 Prenatal Fetal Surveillance (Content last reviewed: 15th December 2018)
- Chapter 10 Fetal Growth Disorders (Content last reviewed: 15th March 2020)
- Chapter 11 Disorders of Amniotic Fluid (Content last reviewed: 15th March 2020)
- Chapter 12 Fetal Hemolytic Disease (Content last reviewed: 15th February 2018)
- Chapter 13 Fetal Thrombocytopenia (Content last reviewed: 15th March 2020)
- Chapter 14 Fetal Cardiac Arrhythmias (Content last reviewed: 15th March 2020)
- Chapter 15 Fetal Cardiac Abnormalities (Content last reviewed: 15th March 2020)
- Chapter 16 Fetal Craniospinal and Facial Abnormalities
- Chapter 17 Fetal Genitourinary Abnormalities (Content last reviewed: 15th March 2020)
- Chapter 18 Fetal Gastrointestinal and Abdominal Abnormalities (Content last reviewed: 15th February 2018)
- Chapter 19 Fetal Skeletal Abnormalities
- Chapter 20 Fetal Tumors (Content last reviewed: 15th February 2018)
- Chapter 21 Fetal Hydrops (Content last reviewed: 15th March 2020)
- Chapter 22 Fetal Death
- Section 4 Problems Associated with Infection
- Chapter 24 Hepatitis Virus Infections in Pregnancy (Content last reviewed: 23rd July 2019)
- Chapter 25 Human Immunodeficiency Virus in Pregnancy (Content last reviewed: 23rd July 2019)
- Chapter 26 Rubella, Measles, Mumps, Varicella, and Parvovirus in Pregnancy (Content last reviewed: 11th November 2020)
- Chapter 27 Cytomegalovirus, Herpes Simplex Virus, Adenovirus, Coxsackievirus, and Human Papillomavirus in Pregnancy (Content last reviewed: 11th November 2020)
- Chapter 28 Parasitic Infections in Pregnancy (Content last reviewed: 15th June 2018)
- Chapter 29 Other Infectious Conditions in Pregnancy (Content last reviewed: 11th November 2020)
- Section 5 Late Pregnancy – Maternal Problems
- Section 6 Late Prenatal – Obstetric Problems
- Section 7 Postnatal Problems
- Section 8 Normal Values
- Index
- References
Summary
During normal fetal life, the platelet count progressively increases, reaching a level of approximately 150 × 109/L by the end of the first trimester. Thus, healthy fetuses and neonates have platelet counts within the normal range for adults (150–450 × 109/L). Therefore, fetal and neonatal thrombocytopenia is defined as a platelet count < 150 × 109/L regardless of gestational age. For severe thrombocytopenia with a risk of bleeding problems, a cutoff of 30–50 × 109/L is commonly used. Thus, many mild to moderately thrombocytopenic neonates show no symptoms, and the disease may go unnoticed.
- Type
- Chapter
- Information
- High-Risk PregnancyManagement Options, pp. 308 - 320Publisher: Cambridge University PressFirst published in: 2017
References
Sola-Visner, M, Saxonhouse, MA, Brown, RE. Neonatal thrombocytopenia: what we do and don’t know. Early Hum Dev 2008; 84: 499–506.CrossRefGoogle Scholar
Kamphuis, MM, Paridaans, N, Porcelijn, L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010; 117: 1335–43.CrossRefGoogle ScholarPubMed
Chakravorty, S, Roberts, I. How I manage neonatal thrombocytopenia. Br J Haematol 2012; 156: 155–62.CrossRefGoogle Scholar
Kaplan, C. Platelet alloimmunity: the fetal/neonatal alloimmune thrombocytopenia. Vox Sang 2002; 83 (Suppl 1): 289–91.Google Scholar
Warwick, RM, Vaughan, J, Murray, N, Lubenko, A, Roberts, I. In vitro culture of colony forming unit-megakaryocyte (CFU-MK) in fetal alloimmune thrombocytopenia. Br J Haematol 1994; 88: 874–7.CrossRefGoogle ScholarPubMed
Spencer, JA, Burrows, RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001; 41: 45–55.CrossRefGoogle ScholarPubMed
Killie, MK, Husebekk, A, Kjeldsen-Kragh, J, Skogen, B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008; 93: 870–7.CrossRefGoogle ScholarPubMed
Kamphuis, MM, Paridaans, NP, Porcelijn, L, Lopriore, E, Oepkes, D. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics 2014; 133: 715–21.Google Scholar
Gaddipati, S, Berkowitz, RL, Lembet, AA, et al. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol 2001; 185: 976–80.Google Scholar
Birchall, JE, Murphy, MF, Kaplan, C, Kroll, H; European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of feto–maternal alloimmune thrombocytopenia. Br J Haematol 2003; 122: 275–88.CrossRefGoogle ScholarPubMed
Yougbare, I, Lang, S, Yang, H, et al. Maternal anti-platelet beta3integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest 2015; 125: 1545–56.Google Scholar
Santoso, S, Wihadmadyatami, H, Bakchoul, T, et al. Antiendothelial αvβ3 antibodies are a major cause of intracranial bleeding in fetal/neonatal alloimmune thrombocytopenia. Arterioscler Thromb Vasc Biol 2016; 36: 1517–24. https://doi.org/10.1161/ATVBAHA.116.307281.CrossRefGoogle Scholar
Bussel, JB, Zabusky, MR, Berkowitz, RL, McFarland, JG. Fetal alloimmune thrombocytopenia.N Engl J Med 1997; 337: 22–6.CrossRefGoogle ScholarPubMed
Kaplan, C, Murphy, MF, Kroll, H, Waters, AH. Feto-maternal alloimmunethrombocytopenia: antenatal therapy with IvIG and steroids –more questions than answers. European Working Group on FMAIT. Br J Haematol 1998; 100: 62–5.CrossRefGoogle Scholar
Scheffer, PG, Ait Soussan, A, Verhagen, OJ, et al. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG 2011; 118: 1392–5.CrossRefGoogle ScholarPubMed
Kamphuis, MM, Oepkes, D. Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions. Prenat Diagn 2011; 31: 712–19.CrossRefGoogle ScholarPubMed
Pacheco, LD, Berkowitz, RL, Moise, KJ, et al. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol 2011; 118: 1157–63.Google Scholar
Hansen, RJ, Balthasar, JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002; 88: 898–9.Google Scholar
Paridaans, NP, Kamphuis, MM, Taune Wikman, A, et al. Low-dose versus standard-dose intravenous immunoglobulin to prevent fetal intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia: a randomized trial. Fetal Diagn Ther 2015; 38: 147–53.CrossRefGoogle ScholarPubMed
Kamphuis, MM, Paridaans, NP, Wikman, A, et al. Lower dose intravenous immunoglobulins for the treatment of fetal and neonatal alloimmune thrombocytopenia: a cohort study. Tranfusion 2016; 56: 2308–13.CrossRefGoogle ScholarPubMed
Winkelhorst, D, Murphy, MF, Greinacher, A, et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood 2017; 129: 1538–47. doi: 10.1182/blood-2016-10-739656.CrossRefGoogle ScholarPubMed
van den Akker, ES, Oepkes, D, Lopriore, E, Kanhai, HH. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007; 14: 469–73.Google Scholar
Berkowitz, RL, Lesser, ML, McFarland, JG, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol 2007; 110: 249–55.CrossRefGoogle ScholarPubMed
van den Akker, E, Oepkes, D, Brand, A, Kanhai, HH. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia? BJOG 2006; 113: 781–3.Google Scholar
te Pas, AB, Lopriore, E, van den Akker, ES, et al. Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG. Eur J Pediatr 2007; 166: 1057–63.CrossRefGoogle ScholarPubMed
Van Der Lugt, NM, Kamphuis, MM, Paridaans, NP, et al. Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin. Blood Transfus 2015; 13: 66–71.Google Scholar
Kjeldsen-Kragh, J, Husebekk, A, Killie, MK, Skogen, B. Is it time to include screening for neonatal alloimmune thrombocytopenia in the general antenatal health program? Transfus Apher Sci 2008; 38: 183–8.CrossRefGoogle Scholar
Kjeldsen-Kragh, J, Skogen, B. Mechanisms and Prevention of Alloimmunization in Pregnancy. Obstet Gynecol Surv 2013; 68: 526–32Google Scholar
Care, A, Pavord, S, Knight, M, Alfirevic, Z. Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study. BJOG 2018; 125: 604–12. doi: 10.1111/1471-0528.14697.Google Scholar
Gernsheimer, T, McCrae, KR. Immune thrombocytopenic purpura in pregnancy. Curr Opin Hematol 2007; 14: 574–80.Google Scholar
Sainio, S, Joutsi, L, Jarvenpaa, AL, et al. Idiopathic thrombocytopenic purpura in pregnancy. Acta Obstet Gynecol Scand 1998; 77: 272–7.Google Scholar
Samuels, P, Bussel, JB, Braitman, LE, et al. Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. N Engl J Med 1990; 323: 229–35.CrossRefGoogle ScholarPubMed
Fujimura, K, Harada, Y, Fujimoto, T, et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol 2002; 75: 426–33.CrossRefGoogle ScholarPubMed
Koyama, S, Tomimatsu, T, Kanagawa, T,et al. Reliable predictors of neonatal immune thrombocytopenia in pregnant women with idiopathic thrombocytopenic purpura. Am J Hematol 2012; 87: 15–21.Google Scholar
Hachisuga, K, Hidaka, N, Fujita, Y, Fukushima, K, Kato, K. Can we predict neonatal thrombocytopenia in offspring of women with idiopathic thrombocytopenic purpura? Blood Res 2014; 49: 259–64.Google Scholar
Payne, SD, Resnik, R, Moore, TR, et al. Maternal characteristics and risk of severe neonatal thrombocytopenia and intracranial hemorrhage in pregnancies complicated by auto immune thrombocytopenia. Am J Obstet Gynecol 1997; 177: 149–55.CrossRefGoogle Scholar
Cines, DB, Bussel, JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106: 2244–51.Google Scholar
Calderwood, C. Thromboembolism and thrombophilia in pregnancy. Curr Obstet Gynaecol 2006; 16: 321–6.Google Scholar
Kelton, JG. Idiopathic thrombocytopenic purpura complicating pregnancy. Blood Rev 2002; 16: 43–6.CrossRefGoogle ScholarPubMed
Gernsheimer, T, James, AH, Stasi, R. How I treat thrombocytopenia in pregnancy. Blood 2013; 121: 38–47.CrossRefGoogle Scholar
Committee for Standards in Haematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Haematol 2003; 120: 574–96.Google Scholar
George, JN, Woolf, SH, Raskob, GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society. Blood 1996; 88: 3–40.CrossRefGoogle ScholarPubMed
Provan, D, Stasi, R, Newland, AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168–86CrossRefGoogle ScholarPubMed
Sun, D, Shehata, N, Ye, XY, et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood 2016; 128: 1329–35. doi: 10.1182/blood-2016-04-710285.Google Scholar
Kong, Z, Qin, P, Xiao, S, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood 2017; 130: 1097–103.CrossRefGoogle ScholarPubMed
Choi, S, Brull, R. Neuraxial techniques in obstetric and non-obstetric patients with common bleeding diatheses. Anesth Analg 2009; 1092: 648–60.Google Scholar
van Veen, JJ, Nokes, TJ, Makris, M. The risk of spinal haematoma following neuraxial anaesthesia. Br J Haematol 2010; 1481: 15–25.Google Scholar
Bakchoul, T, Bassler, D, Heckmann, M, et al. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. Transfusion 2014; 54: 640–5. https://doi.org/10.1111/trf.12336.Google Scholar
Pass, RF, Fowler, KB, Boppana, SB, et al. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J ClinVirol 2006; 35: 216–20Google Scholar
Boppana, SB, Pass, RF, Britt, WJ, et al. Symptomatic congenital cytomegalovirus infection: Neonatal morbidity and mortality. Pediatr Infect Dis J 1992; 11: 93–9.Google Scholar
Ortiz, JU, Ostermayer, E, Fischer, T, et al. Severe fetal cytomegalovirus infection associated with cerebellar hemorrhage. Ultrasound Obstet Gynecol 2004; 23: 402–6.Google Scholar
Hohlfeld, P, Forestier, F, Kaplan, C, et al. Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood 1994; 84: 1851–6.Google Scholar
Segata, M, Chaoui, R, Khalek, N, et al. Fetal thrombocytopenia secondary to parvovirus infection. Am J Obstet Gynecol 2007; 196: 61.e1–4.Google Scholar
de Haan, TR, van den Akker, ES, Porcelijn, L, et al. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG 2008; 115: 76–81.Google Scholar
van den Akker, ES, de Haan, TR, Lopriore, E, et al. Severe fetal thrombocytopenia in Rhesus D alloimmunized pregnancies. Am J Obstet Gynecol 2008; 199: 387.e1–4.Google Scholar
van den Akker, ES, Klumper, FJ, Brand, A, et al. Kell alloimmunization in pregnancy: associated with fetal thrombocytopenia? Vox Sang 2008; 95: 66–9.Google Scholar
Van Kamp, IL, Klumper, FJ, Oepkes, D, et al. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005; 192: 171–7.Google Scholar
Hohlfeld, P, Forestier, F, Vial, Y, Tissot, JD. Hematological features of fetal triploidy: A report of 11 cases. Biol Neonate 1997; 72: 279–83.Google Scholar
Henry, E, Walker, D, Wiedmeier, SE, Christensen, RD. Hematological abnormalities during the first week of life among neonates with Down syndrome: Data from a multihospital healthcare system. Am J Med Genet 2007; 143: 42–50.Google Scholar
Wiedmeier, SE, Henry, E, Christensen, RD: Hematological abnormalities during the first week of life among neonates with trisomy 18 and trisomy 13: data from a multi-hospital healthcare system. Am J Med Genet 2008; 146: 312–20.Google Scholar
Watts, TL, Roberts, IAG. Haematological abnormalities in the growth-restricted infant. Semin Neonatol 1999; 4: 41–54.Google Scholar
Tunstall-Pedoe, O, de la Fuente, J, Bennett, PR, et al. Trisomy 21 expands the megakaryocyte-erythroid progenitor compartment in human fetal liver: implications for Down syndrome AMKL. Blood 2006; 108: 170a.Google Scholar
Roberts, I, Stanworth, S, Murray, NA. Thrombocytopenia in the neonate. Blood Rev 2008; 22: 173–86.Google Scholar
Geddis, AE. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol Oncol Clin North Am 2009; 23: 321–31.CrossRefGoogle ScholarPubMed
López, JA, Andrews, RK, Afshar-Kharghan, V, Berndt, MC. Bernard–Soulier syndrome. Blood 1998; 91: 4397–418.Google Scholar
Fujimori, K, Ohto, H, Honda, S, Sato, A. Antepartum diagnosis of fetal intracranial hemorrhage due to maternal Bernard–Soulier syndrome. Obstet Gynecol 1999; 94: 817–19.Google Scholar
Jimenez-Rivera, C, Gupta, A, Feberova, J, de Nanassy, JA, Boland, MP. Successful treatment of neonatal hemochromatosis as gestational alloimmune liver disease with intravenous immunoglobulin. J Neonatal Perinatal Med 2014; 7: 301–4.Google Scholar
Holmberg, L, Gustavii, B, Jönsson, A. A prenatal study of fetal platelet count and size with application to fetus at risk for Wiskott–Aldrich syndrome. J Pediatr 1983; 102: 773–6.Google Scholar
Krishnamurti, L, Neglia, JP, Nagarajan, R, et al. Paris–Trousseau syndrome platelets in a child with Jacobsen’s syndrome. Am J Hematol 2001; 66: 295–9.Google Scholar
Drachman, JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103: 390–8.Google Scholar
Overton, TG, Duncan, KR, Jolly, M, et al. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal out-come. Am J Obstet Gynecol 2002; 186: 826–31.Google Scholar
Madani, K, Kamphuis, MM, Lopriore, E, Porcelijn, L, Oepkes, D. Delayed diagnosis of fetal and neonatal alloimmune thrombocytopenia: a cause of perinatal mortality and morbidity. BJOG 2012; 119: 1612–16.Google Scholar